48 weeks of adefovir mono therapy following 48 weeks of combination therapy with peginterferon alfa-2b and adefovir leads to additional biochemical and virological improvement
M Lütgehetmann, K Wursthorn, B Zöllner, P Buggisch, M Zankel, C Fischer, C Brosgart, J Petersen · Zeitschrift für Gastroenterologie · 2006 · Heft 09
Bibliografische Angaben
Zusammenfassung
Background and aim: Administration of 48 weeks of PEG-IFN alfa-2b and adefovir (ADV) combination therapy in chronically HBV infected patients resulted in a strong suppression of cccDNA, high rates of HBsAg seroconversion, and HBeAg seroconversion and loss, respectively (Wursthorn, EASL 2005). However, most HBV patients may need long-term antiviral therapy. The aim of the study is to determine virological and serological outcome including cccDNA in chronic Hepatitis B patients after 48 weeks of PEG-IFN alfa-2b and ADV therapy followed by 96 weeks of ADV mono therapy. Here we report on the interims analysis after…
